Improved survival at the population level for patients with advanced Merkel cell carcinoma following availability of immunotherapy
{{output}}
Background: Merkel cell carcinoma (MCC) is an aggressive skin cancer with poor survival rates. Immune checkpoint inhibitors (ICIs) were FDA-approved for advanced MCC in 2017, but their real-world survival impact remains unclear. ... ...
